Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-DCM
NCT01020968Phase 2Completed
- Sponsor
- Vericel
- Start
- Dec 2009
- Primary completion
- Jan 2012
- Modality
- Mesenchymal Stem Cells, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ixmyelocel-T in dilated cardiomyopathy (DCM), sponsored by Vericel. Started Dec 2009; status: completed.
02
Drugs
ixmyelocel-T
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT01020968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01020968.